Novel N-Methylated Cyclodepsipeptide Prodrugs for Targeted Cancer Therapy.
Basic Information
ID: ALA4732139
Journal: J Med Chem
Title: Novel N-Methylated Cyclodepsipeptide Prodrugs for Targeted Cancer Therapy.
Authors: Wu C,Cheng Z,Lu D,Liu K,Cheng Y,Wang P,Zhou Y,Li M,Shao X,Li H,Su W,Fang L
Abstract: Coibamide A (1) is a highly N-methylated cyclodepsipeptide with low nanomolar antiproliferative activities against various cancer cell lines. In previous work, we discovered a simplified analogue, [MeAla3-MeAla6]-coibamide (1a), which exhibited the same inhibitory abilities as coibamide A. Herein, to reduce the whole-body toxicity and improve the solubility of 1a, two novel peptide-drug conjugates RGD-SS-CA (2) and RGD-VC-CA (3) were designed, synthesized, and evaluated. Composed of cyclodepsipeptide 1a, a tumor-homing RGD motif, and a conditionally labile linker, the conjugates are expected to release 1a tracelessly in specific tumor microenvironments. Compared with RGD-VC-CA (3), RGD-SS-CA (2) proved to be superior in in vitro drug release and cytotoxicity tests. Notably, intravenous injection of RGD-SS-CA (2) into mice-bearing human tumor xenografts induced significant tumor growth suppression with negligible toxicity. Therefore, as a novel prodrug of the coibamide A analogue, conjugate 2 has great potential for further exploration in cancer drug discovery.
CiteXplore: 33417771
DOI: 10.1021/acs.jmedchem.0c01387
Patent ID: ┄